Northpointe Capital’s Bristol-Myers Squibb BMY Stock Holding History

Northpointe Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$3.77M	Buy	74,424 +59,058	+384%	+$2.78M	1.46%	23
2019 Q2	$697K	Sell	15,366 -28,958	-65%	-$1.35M	0.22%	82
2019 Q1	$2.12M	Sell	44,324 -28,823	-39%	-$1.44M	0.67%	68
2018 Q4	$3.8M	Buy	+73,147	New	+$3.93M	0.86%	30
2017 Q3	–	Sell	-37,626	Closed	-$2.1M	–	173
2017 Q2	$2.1M	Buy	+37,626	New	+$2.05M	0.22%	153
2016 Q1	–	Sell	-47,471	Closed	-$2.81M	–	239
2015 Q4	$2.81M	Hold	47,471	–	–	0.37%	105
2015 Q3	$2.81M	Buy	47,471 +4,836	+11%	+$307K	0.37%	106
2015 Q2	$2.84M	Buy	+42,635	New	+$2.81M	0.33%	102
2014 Q1	–	Sell	-17,870	Closed	-$951K	–	238
2013 Q4	$951K	Buy	+17,870	New	+$910K	0.08%	207

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northpointe Capital's BMY Position: Q3 2019 in Review

Northpointe Capital increased its Bristol-Myers Squibb (BMY) stake by 384% in Q3 2019, buying an estimated $2.78M and bringing the position to 74,424 shares worth $3.77M. The position accounts for 1.46% of the portfolio, ranked #23.

Northpointe Capital first reported a position in BMY in Q4 2013 and has held it in 9 quarters since. The position peaked at $3.8M in Q4 2018. 1,814 funds tracked by Wall St. Rank hold BMY as of Q3 2019.

Northpointe Capital held 74,424 shares of Bristol-Myers Squibb worth $3.77M as of Q3 2019.
Northpointe Capital bought 59,058 Bristol-Myers Squibb shares in Q3 2019, an estimated $2.78M.
Bristol-Myers Squibb made up 1.46% of Northpointe Capital's portfolio in Q3 2019, its #23 holding.
Northpointe Capital first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 9 quarters since.
Northpointe Capital's Bristol-Myers Squibb position peaked at $3.8M in Q4 2018.
1,814 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2019.

Based on Northpointe Capital's 13F filing for Q3 2019, filed 16 Oct 2019.